Emoto Makoto, Yoshihisa Hajime, Yano Kyoko, Choijamts Batsuren, Tsugu Hitoshi, Tachibana Katsuro, Aizawa Mamoru
Department of Health and Welfare, International University of Health and Welfare, Sawara-ku, Fukuoka, Japan Division of Gynecology in Preventive Medicine, Fukuoka Sanno Hospital, Sawara-ku, Fukuoka, Japan
Department of Applied Chemistry, School of Science and Technology, Meiji University, Tama-ku, Kawasaki, Japan.
Anticancer Res. 2015 Sep;35(9):4757-64.
The purpose of the present study was to develop an advanced method of anti-angiogenic chemoembolization to target morphological vascular heterogeneity in tumors and further the therapeutic efficacy of cancer treatment. This new chemoembolization approach was designed using resorbable calcium-phosphate ceramic microspheres (CPMs), in a mixture of three different sizes, which were loaded with an anti-angiogenic agent to target the tumor vasculature in highly angiogenic solid tumors in humans in vivo. The human uterine carcinosarcoma cell line, FU-MMT-3, was used in this study because the tumor is highly aggressive and exhibits a poor response to radiotherapy and chemotherapeutic agents that are in current use. CPMs loaded with TNP-470, an anti-angiogenic agent, were injected into FU-MMT-3 xenografts in nude mice three times per week for 8 weeks. The treatment with TNP-470-loaded CPMs of three different diameters achieved a greater suppression of tumor growth in comparison to treatment with single-size TNP-470-loaded CPMs alone, and the control. Severe loss of body weight was not observed in any mice treated with any size of TNP-470-loaded CPMs. These results suggest that treatment with a mixture of differently-sized anti-angiogenic CPMs might be more effective than treatment with CPMs of a single size. This advanced chemoembolization method, which incorporated an anti-angiogenic agent to target the morphological vascular heterogeneity of tumors may contribute to effective treatment of locally advanced or recurrent solid tumors.
本研究的目的是开发一种先进的抗血管生成化疗栓塞方法,以针对肿瘤中的形态学血管异质性,进而提高癌症治疗的疗效。这种新的化疗栓塞方法是使用可吸收的磷酸钙陶瓷微球(CPM)设计的,这些微球有三种不同大小的混合尺寸,并负载了一种抗血管生成剂,用于在体内靶向人类高血管生成性实体瘤中的肿瘤血管系统。本研究使用了人子宫癌肉瘤细胞系FU-MMT-3,因为该肿瘤具有高度侵袭性,并且对目前使用的放疗和化疗药物反应不佳。将负载抗血管生成剂TNP-470的CPM每周三次注射到裸鼠的FU-MMT-3异种移植瘤中,持续8周。与单独使用单一尺寸负载TNP-470的CPM治疗以及对照组相比,用三种不同直径的负载TNP-470的CPM进行治疗对肿瘤生长的抑制作用更大。在用任何尺寸的负载TNP-470的CPM治疗的任何小鼠中均未观察到严重的体重减轻。这些结果表明,用不同大小的抗血管生成CPM混合物进行治疗可能比用单一尺寸的CPM治疗更有效。这种先进的化疗栓塞方法,通过结合抗血管生成剂来靶向肿瘤的形态学血管异质性,可能有助于有效治疗局部晚期或复发性实体瘤。